EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 3.0

Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials

Jaewon Hyung, Minsu Kang, Ilhwan Kim, Kyu-Pyo Kim, Baek-Yeol Ryoo, Jaekyung Cheon, Hyewon Ryu, Ji Sung Lee, Ji-Won Kim, In Sil Choi, Jin Hyun Park, Ghassan K Abou-Alfa und 2 weitere

Cancer Research and Treatment · 2025

DOI: 10.4143/crt.2024.652 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Jaewon Hyung und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NCI NIH HHS, Asan Institute for Life Sciences, Asan Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PurposeWhile fluoropyrimidine-based chemotherapy regimens are recommended second-line treatment for patients with advanced biliary tract cancer (BTC), there have been no studies comparing different regimens head-to-head.Materials and Methods We performed individual patient-level meta-analysis based on data from the intention-to-treat population of the phase 2b NIFTY trial (liposomal irinotecan [nal-IRI] plus fluorouracil and leucovorin [5-FU/LV] vs. 5-FU/LV; NCT03542508) and the phase 2 FIReFOX trial (modified oxaliplatin plus 5-FU/LV [mFOLFOX] vs. modified irinotecan plus 5-FU/LV [mFOLFIRI]; NCT03464968). Pairwise log-rank tests and multivariable analysis using Cox proportional hazards modeling with shared frailty to account for the trial's effect were used to compare overall survival (OS) between regimens.

Results

A total of 277 patients were included. The nal-IRI plus 5-FU/LV group (n=88) showed significantly better OS compared to the mFOLFOX group (n=49, pairwise log-rank, p=0.02), and mFOLFIRI group (n=50, p=0.03). Multivariable analysis showed consistent trends in OS with adjusted hazard ratios of 1.39 (mFOLFOX vs. nal-IRI plus 5-FU/LV: 95% confidence interval [CI], 0.93 to 2.07; p=0.11) and 1.36 (mFOLFIRI vs. nal-IRI plus 5-FU/LV: 95% CI, 0.92 to 2.03; p=0.13), respectively. Compared to the 5-FU/LV group, the mFOLFOX group and the mFOLFIRI group did not show differences in terms of OS (pairwise log-rank p=0.83 and p=0.58, respectively). The nal-IRI plus 5-FU/LV group experienced more frequent diarrhea, while the mFOLFOX group experienced peripheral neuropathy.

Conclusion

Nal-IRI plus 5-FU/LV showed favorable survival outcomes compared to mFOLFOX, mFOLFIRI, or 5-FU/LV. The safety profiles of these regimens should be considered along with efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsAgedFemaleHumansMaleMiddle AgedFluorouracilLeucovorinRandomized Controlled Trials as TopicTreatment OutcomeClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

Biliary tract neoplasmsFluoropyrimidineLiposomal irinotecan

Substanzen

FluorouracilLeucovorin

Autor:innen und Institutionen

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Division of Oncology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
  • Division of Hematology and Oncology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
  • Division of Hematology and Oncology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea.
  • Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Förderung

  • NCI NIH HHS
  • Asan Institute for Life Sciences, Asan Medical Center

Zitieren

APA

Hyung, J., Kang, M., Kim, I., Kim, K. P., Ryoo, B. Y., Cheon, J., Ryu, H., Lee, J. S., Kim, J. W., Choi, I. S., Park, J. H., Abou-Alfa, G. K., Kim, J. W., & Yoo, C. (2025). Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.652

Vancouver

Hyung J, Kang M, Kim I, Kim KP, Ryoo BY, Cheon J, et al. Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.652

BibTeX
@article{Hyung2025,
  author = {Hyung, Jaewon and Kang, Minsu and Kim, Ilhwan and Kim, Kyu-Pyo and Ryoo, Baek-Yeol and Cheon, Jaekyung and Ryu, Hyewon and Lee, Ji Sung and Kim, Ji-Won and Choi, In Sil and Park, Jin Hyun and Abou-Alfa, Ghassan K and Kim, Jin Won and Yoo, Changhoon},
  title = {Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials},
  journal = {Cancer Research and Treatment},
  year = {2025},
  doi = {10.4143/crt.2024.652}
}
Kostenlos starten →